Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib Effect on Midazolam PK in Advanced Solid Tumours
NCT04958226Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of capivasertib in solid neoplasms, sponsored by AstraZeneca. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Zero to Infinity for Midazolam and Maximum Plasma Concentration for Midazolam. Started Oct 2021; status: completed.
02
Drugs
capivasertib
03
Conditions
solid neoplasms
Beyond the preview
Go deeper on NCT04958226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958226.